Company ProfilePremium

Verona Pharma PLC

Company Profile Analysis

Ticker: VRP.L

ESOMAR 23 Corporate BadgeISO Certifications Badge
Verona Pharma PLC - Company showcase

Year Founded & Workforce

2005

Verona Pharma PLC logo

Verona Pharma PLC Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Verona Pharma PLC Overview

Verona Pharma was a single-asset respiratory specialty pharmaceutical company that converted a four-decade-old molecule into one of the most successful commercial launches in modern respiratory medicine, and then monetised it. Its entire enterprise rested on ensifentrine — a first-in-class, inhaled, selective dual inhibitor of phosphodiesterase 3 and 4, marketed as Ohtuvayre — approved by the FDA on 26 June 2024 as the first novel inhaled mechanism for COPD maintenance treatment in more than twenty years. The Company self-commercialised in the United States through a roughly 120-representative field force and an exclusive specialty-pharmacy network, while out-licensing Greater China to Nuance Pharma. Quarterly net product sales rose from USD 5.6 million at launch to USD 102.9 million within four quarters, delivering the Company's first quarterly net income in Q2 2025. Fourteen months after approval, Merck acquired the business for approximately USD 10 billion — a valuation implying peak sales expectations of roughly USD 3–5 billion.


The Company's own characterisation

The Company described itself consistently across its final filings as "a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs" (FY2024 Form 10-K, Item 1; Q2 2025 Form 10-Q, Item 2). Its 10-K described Ohtuvayre as "our first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years" and stated the Company's belief that Ohtuvayre "will redefine the treatment paradigm for COPD."

Independent characterisation

Verona Pharma was, in structural terms, a single-molecule, single-market, asset-light commercial pharmaceutical company. Four features defined the model:

A single asset with multi-indication optionality. Every dollar of enterprise value derived from ensifentrine. The Company acknowledged this explicitly as its foremost risk factor: "We depend solely on the success of ensifentrine" (FY2024 Form 10-K, Summary Risk Factors). The molecule's optionality lay in three vectors — additional indications (non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma), additional formulations (dry powder inhaler, pressurised metered-dose inhaler), and fixed-dose combinations (ensifentrine plus glycopyrrolate).

Asset-light manufacturing. The Company owned no manufacturing facilities. It relied on a single contract manufacturing organisation (CMO) for ensifentrine drug substance and one CMO for each formulation of drug product (FY2024 Form 10-K, "Manufacturing"). This maximised return on invested capital but concentrated supply-chain risk to a degree unusual even for specialty pharma.

Direct US commercialisation, partnered ex-US. In the United States the Company sold directly. Outside the United States, the stated strategy was to "license Ohtuvayre to companies with expertise and experience in developing and commercializing products in those regions." Only one such licence was ever executed — Nuance Pharma for Greater China (June 2021).

Medical-benefit reimbursement, specialty-pharmacy distribution. Ohtuvayre is a nebulised inhalation suspension administered through durable medical equipment, and was reimbursed under the medical benefit rather than the pharmacy benefit — reflected in its permanent product-specific HCPCS J-code (J7601), effective 1 January 2025. Product moved through an exclusive network of five accredited specialty pharmacies (Q2 2025 Form 10-Q, "Concentration of risk").

Revenue model and mix

Revenue streamDescriptionMateriality
US product sales (Ohtuvayre)Net of distribution fees, government rebates and chargebacks, commercial chargebacks, returns, co-pay assistance and other fees100% of FY2024 revenue; 97.1% of H1 2025 revenue
Licensing / milestone incomeNuance Pharma collaboration: USD 40.0m upfront (2021), up to USD 179.0m in clinical, regulatory and commercial milestones, tiered double-digit royalties on Greater China net sales100% of FY2021 revenue; 2.9% of H1 2025 revenue
Clinical supply salesSale of clinical supply materials to Nuance PharmaUSD 0.458m in FY2022 only
Subscription / service revenue—Nil in all periods

Value-chain position, customers and end-markets

Verona occupied the discovery-adjacent-to-commercial band of the value chain: it did not discover ensifentrine (the compound, originally RPL554, was assigned to it via the 2005 Rhinopharma/Vernalis agreement, and traces to the GSK respiratory research programme led by Sir David Jack), and it did not manufacture. It owned clinical development, regulatory strategy, intellectual property, brand, pricing and US commercial execution.

Its economic customers were the five specialty pharmacies that purchased product; its clinical customers were approximately 14,500 targeted US healthcare professionals — pulmonologists, internal-medicine physicians, primary-care physicians, nurse practitioners and physician assistants (FY2024 Form 10-K, "Commercialization"). Its ultimate payers were Medicare Part B, Medicare Advantage and commercial medical-benefit plans.

End-markets served: COPD maintenance treatment (United States, commercial); COPD (Greater China, partnered, approved in Macau); and, in development, non-cystic fibrosis bronchiectasis, cystic fibrosis and asthma.

Financial Narrative

All figures in USD millions unless stated. Basis: US GAAP as presented in the Company's SEC filings and quarterly consolidated financial summaries. FY2020 and FY2021 figures are drawn from the comparative table in the FY2021 results release of 3 March 2022; FY2022 and FY2021 from the FY2022 results release of 7 March 2023; FY2023 and FY2024 from the FY2024 results release and Form 10-K of 27 February 2025. Note that the Company's UK statutory accounts were prepared under IFRS and are not directly comparable line-by-line to the US GAAP presentation below.

Income statement, FY2020–FY2024

EBITDA is approximated as operating loss plus depreciation; depreciation was immaterial (USD 0.533m in H1 2024 and USD 0.588m in H1 2025 per the Q2 2025 Form 10-Q). There was no amortisation of intangibles, as the Company carried no amortisable intangible assets. Loss per ADS is derived by the analyst at the 8:1 ratio and is not a line item in the Company's filings.

Margin analysis

FY2023 percentages are shown as 0 because revenue was nil, rendering revenue-based margins undefined; the underlying operating loss was USD 67.569m. FY2022 margins are shown for completeness but are meaningless given a USD 0.458m revenue base.

Balance sheet, FY2020–FY2024 and H1 2025

Cash, total assets and equity for FY2020–FY2022 are taken from the comparative summaries in the FY2021 and FY2022 results releases; FY2023–FY2024 from the FY2024 Form 10-K balance sheet. Total liabilities for FY2020–FY2022 are derived by the analyst. Goodwill of USD 0.545m is the residual from the 2006 Rhinopharma acquisition and was unchanged in every period reviewed. The Company carried no amortisable intangible assets — the entire ensifentrine patent estate was expensed as incurred, which is why Merck had to capitalise almost the whole purchase price as a new intangible on acquisition.

Balance sheet detail, FY2023 / FY2024 / H1 2025: notes and sources

Sources: FY2024 Form 10-K consolidated balance sheets; Q2 2025 Form 10-Q condensed consolidated balance sheets. Net cash is derived as cash less total interest-bearing obligations (term loan plus RIPSA carrying values).

Cash flow

Source: Q2 2025 Form 10-Q, Condensed Consolidated Statements of Cash Flows. Dividends paid: nil in all periods. Share buybacks: nil in all periods.

Cash flow commentary. The single most important financial inflection in the Company's history occurred in Q2 2025, when operating cash flow turned positive for the first time. H1 2025 delivered USD 19.0 million of operating cash inflow against a USD 30.7 million outflow in H1 2024 — a USD 49.7 million swing driven entirely by Ohtuvayre receipts, partially offset by a USD 51.4 million build in accounts receivable as the specialty-pharmacy channel scaled. Capital expenditure was structurally negligible (USD 0.5 million in H1 2025) — the natural consequence of an asset-light, fully outsourced manufacturing model. Financing activity in H1 2025 was essentially a refinancing exercise: USD 122.5 million drawn on the upsized Tranche C offset by USD 109.9 million to retire the RIPSA, netting USD 12.6 million of new money plus USD 10.1 million from option exercises.

Ratio analysis

Notes: return metrics use end-period balances rather than averages to permit a complete five-year series; using two-point averages, FY2024 ROE would be -76.4% and ROA -44.3%. Interest coverage is shown as 0 where EBIT was negative and the ratio is not meaningful; the H1 2025 figure of 0.18x rises to 1.95x on a Q2 2025-only basis (USD 13.305m operating income over USD 6.822m interest expense). Asset turnover for H1 2025 is annualised revenue over end-period assets.

Cash conversion cycle. In FY2024 the cycle is not meaningful: the Company sold for only five months of the year and inventory metrics are distorted because pre-approval inventory was expensed to R&D rather than capitalised. On H1 2025 data — 181 days, revenue USD 174.195m, cost of sales USD 8.163m — days sales outstanding was approximately 86 days, days inventory outstanding approximately 322 days and days payable outstanding approximately 76 days, implying a cycle of roughly 332 days. The inventory figure overstates true working-capital intensity because reported cost of sales excludes pre-approval production costs already expensed. The genuinely notable number is the 86-day DSO — long for a pharmaceutical business, reflecting medical-benefit reimbursement and specialty-pharmacy payment terms, and a real drag on cash conversion that Merck's scale would compress.

Drivers, inflections and commentary by year

FY2020 — the pivot year. New leadership (Zaccardelli and Hahn, February 2020), a USD 200 million private placement in July, and AIM delisting on 30 October. R&D of USD 44.5 million funded ENHANCE initiation. Net loss USD 65.1 million on nil revenue.

FY2021 — peak clinical burn, offset by the China licence. R&D rose 78% to USD 79.4 million as the bulk of ENHANCE enrolment occurred. The USD 40.0 million Nuance upfront was recognised in full as revenue, cutting the net loss to USD 55.6 million despite higher operating spend. SG&A rose USD 4.1 million, including USD 4.0 million of transaction advisory fees on the Nuance agreement. Cash fell USD 39.6 million to USD 148.4 million.

FY2022 — data year. R&D fell 38% to USD 49.3 million as ENHANCE completed. ENHANCE-2 read out positive in August, ENHANCE-1 in December. SG&A fell to USD 26.6 million, largely on a USD 7.1 million reduction in share-based compensation. Balance sheet rebuilt through a USD 150 million upsized equity raise and a USD 150 million Oxford Finance facility; cash rose to USD 227.8 million. Net loss USD 68.7 million.

FY2023 — pre-commercial build. R&D collapsed 65% to USD 17.2 million with trials complete. SG&A nearly doubled to USD 50.4 million as commercial infrastructure was assembled ahead of the June 2024 PDUFA date. Interest income of USD 12.8 million on a large cash balance materially cushioned the loss, which fell to USD 54.4 million — the lowest in the five-year window. Cash reached USD 271.8 million.

FY2024 — the launch year and the loss peak. Revenue arrived: USD 42.3 million of Ohtuvayre net sales in under five months of selling. But the cost of getting there was severe. SG&A tripled to USD 149.8 million, driven by USD 29.7 million of incremental marketing and commercial activity, USD 26.8 million of people costs as the field force was hired, USD 18.8 million of additional share-based compensation, USD 7.3 million of professional and IT costs, and a USD 15.0 million first-commercial-sale milestone to Ligand. R&D rose to USD 44.6 million on two new Phase 2 starts plus a USD 6.3 million regulatory-approval milestone to Ligand. Below the line, interest expense jumped to USD 23.5 million on the Oaktree/OMERS structures, and a USD 10.3 million tax charge — the first material tax expense in the Company's history — pushed the net loss to USD 173.4 million, the largest ever recorded. Cash nonetheless rose USD 128.0 million to USD 399.8 million on the strength of USD 167.9 million of net debt and RIPSA proceeds plus USD 100 million of Q4 ATM equity.

H1 2025 — the crossover. Product sales of USD 174.2 million in six months exceeded the entire prior-year total by more than four times. Operating income turned positive at USD 2.988 million for the half and USD 13.305 million in Q2 alone. Q2 2025 produced the Company's first quarterly net income: USD 11.921 million. Gross margin on product sales reached 95.4%. The remaining drag was financing cost — USD 17.0 million of interest expense in the half against USD 8.2 million of interest income — and non-cash share-based compensation of USD 72.3 million, which alone exceeded operating income by more than 24 times and is the reason GAAP net income lagged cash generation. Accumulated deficit closed the half at USD 567.1 million.


7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING

Revenue by geography: notes and sources

Sources: FY2021, FY2022 and FY2024 results releases; Q2 2025 Form 10-Q. Geographic attribution is derived by the analyst from the disclosed nature of each revenue stream — the Company did not publish a formal geographic segment note, as it had a single segment and, in the commercial period, a single selling territory.

Country-level detail

United States — 100% of product revenue in every commercial period. Ohtuvayre was approved and marketed only in the United States by Verona itself. Within the US, revenue concentration by customer was extreme: five specialty pharmacies accounted for all product sales and all outstanding product accounts receivable. For the three months ended 30 June 2025, the five accounted for 47%, 31%, 20%, 1% and 1% of net product sales respectively; for the six months, 47%, 29%, 18%, 4% and 2%. The top two customers therefore represented 78% of Q2 2025 net product sales — a concentration the Company flagged explicitly as a risk (Q2 2025 Form 10-Q, "Concentration of risk").

Greater China — partnered, non-consolidated. Revenue from this territory was licence and milestone income, not product sales: USD 40.0 million upfront in FY2021, USD 0.458 million of clinical supply sales in FY2022, and USD 5.0 million in Q1 2025 on Nuance Pharma completing last-patient treatment in its Phase 3 trial. Ohtuvayre's Macau approval in February 2025 was the first ex-US approval anywhere.

Europe and United Kingdom — nil. MAAs were submitted in June 2025 (UK) and July 2025 (EU). The EU application was withdrawn on 30 October 2025 post-acquisition. As of April 2026 the MHRA had not approved Ohtuvayre and no NICE appraisal had been initiated.

Fastest-growing and declining regions

Fastest growing: United States. From nil to USD 174.2 million of half-year revenue in four quarters. Under Merck ownership the trajectory continued: USD 178 million in Q4 2025, USD 131 million in Q1 2026 and USD 204 million in Q2 2026.

Declining: none, structurally — but the ex-US pipeline reversed. The EU withdrawal represents the single clearest deterioration in the geographic story. Merck concluded that continuing the EU MAA process was, in the words of the withdrawal letter, not aligned with current business objectives and portfolio strategy. Whatever the commercial logic, the practical effect is that Ohtuvayre's addressable geography narrowed after the acquisition rather than expanding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Share Count (millions)

MetricFY2020FY2021FY2022FY2023FY2024

Total revenue, net (USD Mn)

040.0000.458042.279

Cost of sales (USD Mn)

000.34602.582

Gross profit (USD Mn)

040.0000.112039.697

Research and development (USD Mn)

44.50579.40649.28317.21644.574

Selling, general and administrative (USD Mn)

29.77233.90726.57950.353149.750

Total operating expenses excluding cost of sales (USD Mn)

74.277113.31375.86267.569194.324

Operating loss (USD Mn)

-74.277-73.313-75.750-67.569-154.627

UK research and development tax credit (USD Mn)

8.26715.6309.6341.1043.600

Interest income (USD Mn)

0.1210.0142.82112.76115.262

Interest expense (USD Mn)

-0.035-0.340-0.521-2.057-23.542

Loss on extinguishment of debt (USD Mn)

00-0.8150-3.653

Fair value movement on warrants (USD Mn)

-1.1362.246000

Foreign exchange gain/(loss) (USD Mn)

2.0600.176-3.8171.866-0.169

Total other income/(expense), net (USD Mn)

9.27717.7267.30213.674-8.502

Loss before income taxes (USD Mn)

-65.000-55.587-68.448-53.895-163.129

Income tax benefit/(expense) (USD Mn)

-0.1460.018-0.253-0.474-10.289

Net loss (USD Mn)

-65.146-55.569-68.701-54.369-173.418

EBITDA, approximate (USD Mn)

-73.7-72.7-75.1-66.9-153.5

Weighted average ordinary shares, basic and diluted (millions)

262.933473.188529.072634.143652.311

Loss per ordinary share, basic and diluted (USD)

-0.25-0.12-0.13-0.09-0.27

Loss per ADS, derived at 8:1 (USD)

-1.98-0.94-1.04-0.69-2.13

Dividends per share (USD)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024

Gross margin on revenue (%)

100.024.5093.9

Operating margin (%)

-183.3-16,539.30-365.7

Net margin (%)

-138.9-14,999.10-410.2

R&D as % of total operating expenses

70.165.025.522.6

SG&A as % of total operating expenses

29.935.074.577.4

Balance Sheet

MetricFY2020FY2021FY2022FY2023FY2024

Cash and cash equivalents (USD Mn)

187.986148.380227.827271.772399.757

Total assets (USD Mn)

204.206186.587259.468308.124474.242

Total liabilities, derived as assets less equity (USD Mn)

19.35238.58229.00258.841269.683

Total shareholders' equity (USD Mn)

184.854148.005230.466249.283204.559

Goodwill (USD Mn)

0.5450.5450.5450.5450.545

Equity interest in Nuance Biotech (USD Mn)

015.00015.00015.00015.000

Financial Analysis

MetricFY2023FY2024H1 2025

Cash and cash equivalents

271,772399,757438,016

Accounts receivable, net

031,49682,858

Inventory, current

06,2498,612

Inventory, long-term

01,9725,910

Tax incentive receivable

10,9545,7624,061

Total current assets

289,708453,572548,851

Right-of-use assets

2,8472,0481,574

Total assets

308,124474,242572,871

Accounts payable

3,49211,2663,434

Accrued expenses

3,58516,75743,328

Total current liabilities

8,69242,68151,238

Term loan, non-current

48,374120,341242,434

RIPSA liability, current plus non-current

0106,1070

Total liabilities

58,841269,683294,598

Accumulated deficit

388,433562,401567,101

Total shareholders' equity

249,283204,559278,273

Working capital, current assets less current liabilities

281,016410,891497,613

Net cash / (net debt)

223,398173,309195,582

Cash Flow

MetricFY2021FY2022FY2023FY2024

Cash and cash equivalents at year end (USD Mn)

148.380227.827271.772399.757

Net change in cash for the year, derived (USD Mn)

-39.60679.44743.945127.985

Returns & Leverage Ratios

MetricH1 2024H1 2025

Net cash provided by/(used in) operating activities (USD Mn)

-30.71219.000

Purchases of furniture and equipment / capex (USD Mn)

-0.045-0.535

Free cash flow, derived (USD Mn)

-30.75718.465

Proceeds from term loans (USD Mn)

122.500122.500

Proceeds from RIPSA (USD Mn)

100.0000

Repurchase of RIPSA (USD Mn)

0-109.921

Repayment of 2023 term loans (USD Mn)

-52.2560

Proceeds from exercise of share options (USD Mn)

0.81610.108

Net cash provided by financing activities (USD Mn)

163.70918.400

Share-based compensation, non-cash (USD Mn)

19.85272.291

Interest paid (USD Mn)

2.02116.397

Income taxes paid (USD Mn)

09.176

Returns & Leverage Ratios (%)

MetricFY2020FY2021FY2022FY2023FY2024

Return on equity, end-period basis (%)

-35.2-37.5-29.8-21.8-84.8

Return on assets, end-period basis (%)

-31.9-29.8-26.5-17.6-36.6

Cash as % of total assets

92.179.587.888.284.3

Equity as % of total assets

90.579.388.880.943.1

Financial Ratios (x) and Key Financials

MetricFY2023FY2024H1 2025

Current ratio (x)

33.3310.6310.71

Debt to equity, all interest-bearing obligations (x)

0.191.110.87

Net debt / (net cash) (USD Mn)

-223.398-173.309-195.582

Asset turnover, revenue over end-period assets (x)

00.090.63

Interest coverage, EBIT over interest expense (x)

000.18

Key Financials

RegionFY2021FY2022FY2023FY2024

United States, product sales (USD Mn)

00042.261

Greater China, licence, milestone and clinical supply (USD Mn)

40.0000.45800.018

Rest of world (USD Mn)

0000

Total (USD Mn)

40.0000.458042.279

Key Financials (Half-Yearly)

RegionH1 2024H1 2025

United States, product sales (USD Mn)

0174.195

Greater China, milestone and other (USD Mn)

05.199

Total (USD Mn)

0179.394

Share Price & Returns

DateEventADS price (USD)

27 April 2017

Nasdaq IPO price

13.50

Jan–Mar 2023

ATM programme — 2,540,173 ADSs for USD 56.9m net; average derived

22.40

30 June 2024

Aggregate market value of voting and non-voting common equity held by non-affiliates: approximately USD 1.1 billion

—

Q4 2024

ATM programme — USD 100m sold at a stated average price

39.35

8 July 2025

Close on the day before announcement

86.86

9 July 2025

Intraday, 10:15 a.m. following announcement (up 21%)

104.79

6–7 October 2025

Final reference price at completion

106.91

Transaction

Consideration per ADS

107.00

Income Statement

MetricQ3 2024Q4 2024Q1 2025Q2 2025

Ohtuvayre net product sales (USD Mn)

5.60036.63771.300102.939

Total net revenue (USD Mn)

5.60036.65576.256103.138

Net income/(loss) (USD Mn)

-43.000-33.827-16.31911.921

Cash and cash equivalents at period end (USD Mn)

336.000399.757401.400438.016

Capital Markets Data

MetricQ4 2025Q1 2026Q2 2026

Ohtuvayre net sales (USD Mn)

178131204

Valuation Snapshot

MetricValueBasis

Transaction value (USD Bn)

10.0

Merck and Verona disclosure

Equity value at USD 107 per ADS (USD Bn)

9.22

Derived: 86,192,121 ADS × USD 107

EV / trailing twelve-month revenue (x)

45.1

Derived: USD 10.0bn / USD 221.65m TTM revenue to Q2 2025

EV / annualised Q2 2025 revenue (x)

24.2

Derived: USD 10.0bn / (USD 103.138m × 4)

EV / consensus FY2025 revenue (x)

24.4

Derived using the reported analyst consensus of approximately USD 409m

EV / implied peak sales at a 3x multiple (USD Bn)

3.0–3.5+

Jefferies commentary at announcement

Premium to undisturbed price (%)

23

USD 107.00 versus the USD 86.86 close on 8 July 2025

Capital Markets

MetricConsensusActualVariance

Q4 2024 revenue (USD Mn)

12.9436.66+183%

Q4 2024 EPS per ADS (USD)

Estimate exceeded

-0.05 per ordinary share

Beat

Q1 2025 revenue (USD Mn)

41.2976.26+85%

Q2 2025 Ohtuvayre net sales (USD Mn)

91.80102.94+12%

FY2025 Ohtuvayre net sales (USD Mn)

402–409

Not comparable — company acquired mid-year

—

Catalyst Details

CatalystExpected timingWhy it matters

Q3 2026 Ohtuvayre sales

Merck Q3 2026 results, expected late October 2026

The cleanest read on underlying demand, since Merck has pre-announced the unwind of Q2 channel timing. A print materially below approximately USD 180m would suggest the Q2 strength was substantially inventory

Phase 2b fixed-dose combination readout

Not publicly dated post-acquisition

The single largest lifecycle value driver; would create a new nebulised category

Phase 2 bronchiectasis readout

Not publicly dated post-acquisition

A positive result opens an indication with no approved therapy

MHRA decision on the UK MAA

Pending since June 2025

Would restore some ex-US optionality; a further withdrawal would confirm a US-only strategy

Any resubmission of the EU MAA

Right expressly reserved in the withdrawal letter

Would reverse the most negative post-deal development

Resolution of the Nuance Pharma buy-back dispute

Unresolved

Determines whether Greater China economics are royalty-based or wholly owned

CMS and payer policy developments affecting Part B / medical-benefit reimbursement

Continuous

Demonstrated to be the dominant short-term swing factor

Competitive readouts — tanimilast, tozorakimab, Nucala in COPD

Ongoing

Would erode the mechanistic monopoly

Any Orange Book patent challenge or paragraph IV certification

Post-June 2028 (four-year NCE window)

The first test of the patent estate

Capital Markets — Transaction value

ItemConflicting valuesResolution

Transaction value

USD 10 billion (Merck, MSD, Verona, all primary releases) versus USD 10.8 billion (Achieve Life Sciences press release, May 2026)

Use USD 10 billion — primary-source consistent. The USD 10.8bn figure appears erroneous or a fully diluted variant

Employee headcount timing

The North Carolina Biotechnology Center reported "209 full-time employees at the end of 2020"; SEC-derived data places 209 at 31 December 2024 with 79 at 31 December 2023

Use 209 at 31 December 2024. The 2020 attribution appears to be a reporting error

Global COPD prevalence

Approximately 384 million (WHO, cited FY2021) versus approximately 392 million (GOLD, cited FY2024)

Use 392 million for current purposes; the difference reflects source and vintage, not a data error

Net cash at 30 June 2025

USD 195.582m derived from the balance sheet (cash USD 438.016m less term loan carrying value USD 242.434m) versus USD 193.64m reported by a third-party aggregator using USD 244.37m of debt

Use the balance-sheet-derived USD 195.582m; the aggregator appears to gross up for accrued items

Executive Leadership

Executive Leadership Team

NameTitleAgeTenure in roleSelected prior rolesEducation

David Zaccardelli, Pharm.D.

President, Chief Executive Officer and Executive Director

60

Since 1 February 2020

President and CEO, Dova Pharmaceuticals (Dec 2018 – Nov 2019, acquired by Swedish Orphan Biovitrum for up to USD 915m); Acting CEO, Cempra (2016–2017); board member, Melinta Therapeutics (2017–2020); COO, Chief Manufacturing Officer and EVP Pharmaceutical Development and Operations, United Therapeutics (2004–2016); earlier clinical research roles at Burroughs Wellcome, Glaxo Wellcome and Bausch & Lomb Pharmaceutical

Pharm.D., University of Michigan

Mark W. Hahn

Chief Financial Officer

62

Since February 2020

CFO, Dova Pharmaceuticals (2018–2019); CFO, Cempra (2010–2017), leading its IPO and follow-on offerings; board member, ALSP Orchid Acquisition Corporation I (2021–2023); began career at Ernst & Young

B.B.A. Accounting and Finance, University of Wisconsin-Milwaukee; CPA (Maryland and North Carolina)

Kathleen Rickard, M.D.

Chief Medical Officer

66

Since February 2019

CMO, Aerocrine AB and subsequently Circassia (2011–2019); Chief Compliance Officer, Aerocrine (2014–2019); VP Clinical Development and Medical Affairs, GlaxoSmithKline Respiratory Medicines Development Centre, with 15 years in GSK's global respiratory franchise

M.D., Hahnemann University Hospital, Philadelphia

Andrew Fisher

General Counsel

55

Since March 2024

Founder, Andrew Fisher LLC consulting practice (2019–2024); EVP, Chief Strategy Officer and Deputy General Counsel, United Therapeutics (2001–2018)

Not disclosed in the proxy

Board of Directors

DirectorRolePrincipal outside affiliation as disclosed

David Ebsworth, Ph.D.

Chairperson of the Board (Non-Executive)

Non-Executive Director, Sartorius AG

David Zaccardelli, Pharm.D.

President, CEO and Executive Director

—

Christina Ackermann

Non-Executive Director (appointed 2024)

Not disclosed in retrieved excerpts

Michael Austwick

Non-Executive Director (appointed 1 February 2024)

Over 15 years of respiratory development and commercialisation leadership

James Brady

Non-Executive Director

Formerly CFO of MedImmune, AstraZeneca's biologics division

Ken Cunningham, M.D.

Non-Executive Director

Non-Executive Chair, Medherant Ltd

Lisa Deschamps

Non-Executive Director

CEO, AviadoBIO Ltd

Martin Edwards, M.D.

Non-Executive Director

Formerly Senior Partner, Novo Holdings A/S

Mahendra Shah, Ph.D.

Non-Executive Director

Senior Fellow, Vivo Capital LLC

Vikas Sinha

Non-Executive Director

CFO, ElevateBio, Inc.

Anders Ullman, M.D., Ph.D.

Non-Executive Director

Head of R&D and Chief Medical Officer, Sobi AB

Rishi Gupta

Non-Executive Director — resigned effective 31 January 2024

Partner, OrbiMed Advisors LLC

Board of Directors (Annual)

DirectorHeld at 31 December 2024Held at 31 December 2023Value at deal price of USD 13.375 per ordinary share (USD)

David Zaccardelli

11,204,75211,766,864149,863,558

David Ebsworth

940,003844,64312,572,540

Martin Edwards

144,800144,8001,936,700

Anders Ullman

334,856334,8564,478,699

Vikas Sinha

74,44074,440995,635

Mahendra Shah

73,08073,080977,445

Lisa Deschamps

70,32070,320940,530

Ken Cunningham

66,58466,584890,561

Christina Ackermann

41,8800560,145

James Brady

000

Michael Austwick

000

Rishi Gupta

000

Directors' Remuneration

Percentage change2024 vs 20232023 vs 20222022 vs 20212021 vs 20202020 vs 2019

Zaccardelli base salary (%)

453371

Zaccardelli short-term incentive (%)

9-1151-2078

Zaccardelli taxable benefits (%)

6-532-3310

Average employee base salary (%)

5610119

Ebsworth base fee (%)

230044

Cunningham base fee (%)

300000

Ullman base fee (%)

330-954

Shah base fee (%)

350———

Targets & Commitments

InitiativeDateDetail and status

USD 650 million strategic financing

9 May 2024

Oaktree Capital and OMERS Life Sciences; non-dilutive; extended cash runway beyond 2026; funded the US launch

US commercial launch of Ohtuvayre

6 August 2024

Exclusive specialty pharmacy network; approximately 120 field staff; speaker education programme with roughly 120 programmes completed by end-2024

Phase 2 fixed-dose combination programme

Q3 2024 initiation

Glycopyrrolate dose-ranging completed; Phase 2b planned H2 2025

Phase 2 bronchiectasis programme

Q3 2024 initiation

Enrolling at final disclosure; targets an indication with no approved therapies

GOLD 2025 inclusion

November 2024

Ohtuvayre added to the GOLD COPD treatment algorithm — a critical guideline-adoption milestone

Permanent J-code (J7601)

Effective 1 January 2025

Removed the principal reimbursement friction for a medical-benefit product

Balance sheet simplification

March 2025

RIPSA repurchased in full; term loan upsized to USD 450 million; interest rate cut from 11.00% to 9.70%; management stated this "increased the Company's financial flexibility, reduced the cost of capital and simplified the balance sheet"

Sales force expansion

Announced April 2025

Approximately 30 additional sales representatives planned for Q3 2025 to deepen the prescriber base

EU and UK regulatory filings

June–July 2025

MAAs submitted to MHRA and EMA; the EU application was subsequently withdrawn on 30 October 2025

Greater China buy-back

24 June 2025

Buy-Back Notice served on Nuance Pharma to reacquire the licence, sublicences and related assets — a decisive strategic reversal from the partnering model, disputed by Nuance and unresolved at completion

Sale of the Company

8 July 2025

Transaction Agreement with Merck at USD 107 per ADS

Competitive Landscape

Key Competitors

CompetitorOwnerProduct(s)ClassDeliveryCompetitive relationship to Ohtuvayre

Trelegy Ellipta

GSK plc

fluticasone furoate / umeclidinium / vilanterol

Triple ICS/LAMA/LABA

DPI

The dominant COPD brand and Ohtuvayre's principal share-of-wallet competitor; approximately 50% of Ohtuvayre use was on background triple therapy, so the relationship is more additive than substitutive

Breztri Aerosphere

AstraZeneca plc

budesonide / glycopyrrolate / formoterol

Triple ICS/LAMA/LABA

pMDI

Approved US July 2020, EU December 2020, China December 2019; direct triple-therapy competitor

Trimbow

Chiesi Farmaceutici

beclometasone / formoterol / glycopyrronium

Triple ICS/LAMA/LABA

pMDI

Approved EU 2017; Phase 3 in the US

Symbicort

AstraZeneca plc

budesonide / formoterol

ICS/LABA

DPI/pMDI

Legacy dual therapy; large installed base

Advair, Breo, Anoro

GSK plc

fluticasone/salmeterol; fluticasone furoate/vilanterol; umeclidinium/vilanterol

ICS/LABA and LAMA/LABA

DPI

Legacy franchises; heavily genericised in the case of Advair

Spiriva

Boehringer Ingelheim GmbH

tiotropium

LAMA

DPI/soft mist

Long-standing monotherapy standard

Yupelri

Viatris / Theravance Biopharma

revefenacin

LAMA

Nebulised

The most direct nebulised competitor; competes for the same delivery-modality patient

Brovana

Sunovion / Sumitomo

arformoterol

LABA

Nebulised

Nebulised competitor

Perforomist

Viatris

formoterol

LABA

Nebulised

Nebulised competitor

Daliresp

AstraZeneca plc

roflumilast

Oral PDE4 inhibitor

Oral

Mechanistically closest predecessor; constrained by systemic gastrointestinal toxicity — nausea, emesis, diarrhoea, abdominal pain, appetite loss, weight loss — which Ohtuvayre's inhaled delivery avoids

Dupixent

Sanofi / Regeneron

dupilumab

Anti-IL-4Rα biologic

Injectable

Approved US September 2024 for approximately 300,000 COPD patients with an eosinophilic phenotype; the first injectable biologic in COPD; addresses a narrower population than Ohtuvayre's broad label

Nucala

GSK plc

mepolizumab

Anti-IL-5 biologic

Injectable

Phase 3 for COPD exacerbation prevention at the time of the FY2024 10-K

Tozorakimab

AstraZeneca plc

anti-IL-33

Biologic

Injectable

Phase 3 for COPD exacerbation prevention

Tanimilast

Chiesi Farmaceutici

inhaled PDE4 inhibitor

Inhaled PDE4

Inhaler

The closest mechanistic follower — but single-PDE, not dual

Peer Comparison FY2025

MetricValuePeriodSource

Verona Pharma trailing twelve-month revenue at acquisition (USD Mn)

221.65

Q3 2024 – Q2 2025

Derived from Verona quarterly filings

Verona Pharma trailing twelve-month net loss at acquisition (USD Mn)

-81.22

Q3 2024 – Q2 2025

Derived from Verona quarterly filings

Verona Pharma gross margin on product sales (%)

95.4

Q2 2025

Q2 2025 Form 10-Q

Verona Pharma R&D intensity, R&D over revenue (%)

15.1

H1 2025

Q2 2025 Form 10-Q

Merck total worldwide sales (USD Bn)

65.0

FY2025

Merck FY2025 results

Merck Keytruda/Keytruda Qlex sales (USD Bn)

31.7

FY2025

Merck FY2025 results

Merck Winrevair sales (USD Bn)

1.4

FY2025

Merck FY2025 results

Johnson & Johnson PAH franchise revenue (USD Bn)

4.43

FY2025

Reported in industry coverage of Merck's Q4 2025

Recent Developments

--

Company Snapshot

2005

Founded

Wales, United Kingdom

Headquarters

SWOT Analysis

Strengths

  • Genuine first-in-class status with no clinical-stage follower. The FY2024 Form 10-K states no other dual PDE3/PDE4 inhibitor is on the market or in clinical development in the US or Europe — an unusually durable form of differentiation.
  • Exceptional gross margin. Cost of sales was 4.6% of product sales in FY2024 and 4.6% in Q2 2025, giving a 95.4% product gross margin — top-decile even for branded pharmaceuticals.
  • Launch velocity. Net product sales rose from USD 5.6 million (Q3 2024) to USD 102.9 million (Q2 2025) — an 18-fold increase in four quarters, with Q1 2025 revenue exceeding consensus of USD 41.29 million by 85%.
  • Rapid, broad prescriber adoption. Over 4,600 unique prescribers and approximately 55% of Tier 1 HCPs by February 2025, with more than 275 HCPs prescribing to over 20 patients each; prescribing spread across single, dual and (approximately 50%) triple background therapy.
  • Guideline and reimbursement infrastructure secured early. GOLD 2025 algorithm inclusion in November 2024; permanent J-code J7601 from 1 January 2025.
  • Deep patent estate. 208 issued and pending patents worldwide with expected expiry dates to 2045, including US 12,251,384 expiring June 2044, and four Orange Book listings.
  • Demonstrated operating leverage. Operating income turned positive at USD 13.305 million in Q2 2025 on USD 103.138 million of revenue, and operating cash flow turned positive in the same quarter — 12 months after launch.
  • Capital-efficient outcome. Approximately USD 235 million of R&D across FY2020–FY2024 and just over USD 1 billion raised in total, converted into a USD 10 billion exit.

Weaknesses

  • Absolute single-asset dependency. The 10-K's own language: "We depend solely on the success of ensifentrine." No second molecule existed in any stage of development.
  • Extreme customer concentration. Five specialty pharmacies accounted for all product sales; two represented 78% of Q2 2025 net product sales, and all outstanding product receivables sat with these five.
  • Single-source manufacturing for drug substance and for each formulation, with no manufacturing facilities of its own.
  • Price positioned far above independent value assessment. USD 35,400 per year against ICER's USD 7,500–12,700 benchmark — a formal access and affordability alert.
  • Heavy dilution from equity compensation. Approximately 71 million ordinary shares under option, RSU and PRSU at 30 June 2025 — 10.3% of shares outstanding — with H1 2025 share-based compensation of USD 72.3 million exceeding operating income more than 24-fold.
  • Expensive capital structure. Term loans at 11.00% (reduced to 9.70% in March 2025) plus a 6.50% revenue interest on global net sales until the RIPSA was repurchased; FY2024 interest expense of USD 23.5 million against USD 42.3 million of revenue.
  • Long cash conversion cycle. Approximately 86 days sales outstanding on H1 2025 data, reflecting medical-benefit reimbursement mechanics.
  • No ex-US commercial capability. A single licensee (Nuance) covering one territory, with that relationship itself in dispute from June 2025.

Opportunities

  • Bronchiectasis — up to 500,000 US adults with no specifically approved therapies; Phase 2 enrolling since Q3 2024.
  • Nebulised fixed-dose combination with glycopyrrolate — Company market research identified unmet need for a nebulised fixed-dose combination; Phase 2 dose-ranging completed, Phase 2b planned for H2 2025, patents filed in multiple jurisdictions.
  • DPI and pMDI formulations — proof of concept demonstrated in Phase 2 in COPD, with data consistent across all three formulations, opening the handheld market segment.
  • Cystic fibrosis — Phase 2a lung-function improvement plus preclinical CFTR activation, in a market with orphan incentives and roughly 105,000 diagnosed patients worldwide.
  • Asthma — Phase 2a data showing improvements comparable to high-dose nebulised albuterol with fewer systemic effects, in a market of more than 260 million patients.
  • Greater China — positive pivotal Phase 3 results (May 2025) plus Macau approval, with either royalty economics or, if the buy-back had completed, full ownership.
  • Earlier-line use — the FY2024 Form 10-K notes some HCPs indicated they would consider using Ohtuvayre earlier in the paradigm, including as monotherapy and before ICS.
  • Merck's commercial scale — a global infrastructure and existing cardio-pulmonary franchise (Winrevair) that Verona could never have built.

Threats

  • CMS and payer policy risk, already materialised. Merck attributed the Q1 2026 sequential decline from USD 178 million to USD 131 million to a CMS reimbursement change and Medicare deductible resets.
  • Structural first-quarter seasonality from Medicare deductible resets, flagged by Merck as a recurring feature.
  • Channel-timing distortion. Merck explicitly warned that Q2 2026's USD 204 million benefited from specialty pharmacy purchase timing expected to unwind in Q3 2026 — meaning reported momentum overstates underlying demand.
  • Formulary restriction risk flowing directly from the ICER alert, which warned the price "may lead payers to implement formulary hurdles."
  • Loss of the European opportunity. The EU MAA was withdrawn on 30 October 2025 and, as of April 2026, the MHRA had not approved and no NICE appraisal had been initiated.
  • Biologic encroachment. Dupixent's September 2024 US approval for approximately 300,000 eosinophilic COPD patients, with Nucala and tozorakimab in Phase 3, introduces a differently priced and differently reimbursed competitive vector.
  • Mechanistic followers. Chiesi's inhaled PDE4 inhibitor tanimilast is in Phase 3; several anti-inflammatories and bronchodilators were in Phase 2 for COPD at the date of the last 10-K.
  • Unresolved Nuance dispute. Nuance disputed the Buy-Back Notice and requested its withdrawal; the matter was unresolved at completion and could bear on Greater China economics.
  • Labelled psychiatric warning — including suicidal thoughts and behaviour — creating prescribing caution and a residual pharmacovigilance liability.
  • Integration and talent attrition. Multiple senior commercial leaders departed post-acquisition; by May 2026 the former Chief Commercial Officer, the commercial operations lead and the national sales director had all joined Achieve Life Sciences.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 January 2025Permanent product-specific J-code J7601 becomes effectiveRemoved the principal reimbursement friction for a medical-benefit product; a precondition for the Q1 2025 sales inflection
7 January 2025Preliminary Q4 and FY2024 results: approximately USD 36m Q4 and USD 42m FY net sales; over 3,500 unique prescribers; over 16,000 prescriptions filled, one-third refills; filled prescriptions up over 35% each month in Q4; approximately two weeks of specialty pharmacy inventoryConfirmed the launch was materially ahead of consensus (Q4 consensus USD 12.94m)
February 2025Nuance Pharma announces Macau approval — first regulatory approval outside the USValidated the ex-US regulatory pathway and the partnering model
13 February 2025Announcement of Q4/FY2024 reporting dateRoutine
27 February 2025Q4/FY2024 results and Form 10-K: FY net sales USD 42.3m; net loss USD 173.4m; cash USD 399.8m; over 4,600 unique prescribers and approximately 55% of Tier 1 HCPs prescribing through February; more than 275 HCPs prescribing to over 20 patients each; approximately 50% of use on background triple therapyDemonstrated breadth of adoption across severity and background therapy — the core commercial thesis
18 March 2025DEF 14A and Annual Report to Shareholders filedDirectors' Remuneration Report for FY2024 published
25 March 2025RIPSA repurchased in full under buy-out option with reduced repayment feesRemoved a 6.50% global net sales revenue interest — economically the single most valuable financing action of the year
27 March 2025First Amendment to 2024 Loan Agreement: Tranche C upsized USD 75m to USD 125m and drawn; interest cut 11.00% to 9.70% with step-down to 9.35%; USD 75m working capital basket addedReduced cost of capital and simplified the capital structure ahead of the sale process
March 2025Nuance completes last-patient treatment in China Phase 3, triggering a USD 5.0m milestone (received in Q2 2025)First milestone income since the 2021 upfront
Q1 2025US Patent 12,251,384, expiring June 2044, listed in the Orange Book — a fourth listed patentExtended the nominal exclusivity runway by roughly a decade beyond the original listings
29 April 2025Q1 2025 results: total revenue USD 76.3m; Ohtuvayre net sales USD 71.3m, up 95% sequentially; approximately 25,000 prescriptions filled; quarterly revenue exceeds operating expenses excluding non-cash charges for the first time; cash USD 401.4m; plan announced to add approximately 30 sales representatives in Q3The commercial crossover. Revenue beat consensus of USD 41.29m by 85%
6 May 2025Additional ENHANCE analyses presented at ATS 2025 supporting Ohtuvayre across a broad COPD populationMedical-affairs reinforcement of the broad-label positioning
May 2025Nuance Pharma reports positive pivotal Phase 3 results in mainland ChinaDe-risked the largest ex-US territory
21 May 2025Announcement of June conference participation, including Jefferies Global Healthcare ConferenceRoutine — but the window in which strategic interest crystallised
June 2025UK marketing authorisation application submitted to the MHRAFirst major-market regulatory filing outside the US
Early June 2025More than one third party sends Verona non-binding term sheets regarding a potential Ohtuvayre collaborationEstablished competitive tension short of a bid
24 June 2025Buy-Back Notice served on Nuance Pharma to reacquire the Greater China licence and all related assets; Nuance disputes and requests withdrawalA strategic reversal of the partnering model — and, in retrospect, a move to consolidate global rights ahead of a sale. Unresolved at completion
3 July 2025Merck proposes USD 104 per ADS with a five-day deadline; Verona's ADSs close at USD 91.53; Verona counters at USD 112; Merck responds at USD 107Documented the negotiation dynamics — a 7.7% uplift from Merck's opening bid
8–9 July 2025Transaction Agreement executed and announced: USD 13.375 per ordinary share / USD 107 per ADS; approximately USD 10bn; 23% premium to the USD 86.86 close; ADSs trade up 21% to USD 104.79 in early trading; termination fee approximately USD 100mThe defining corporate event. Merck's largest acquisition since Prometheus Biosciences (USD 10.8bn, 2023) and third-largest ever after Acceleron (USD 11.5bn, 2021)
July 2025EU marketing authorisation application submitted to the EMA (EMEA/H/C/006742)Completed the major-market filing set — briefly
July–August 2025Multiple law firms, including Kahn Swick & Foti LLC, announce investigations into the adequacy of the price and process in the proposed saleStandard deal-related shareholder activity; no material litigation resulted
6 August 2025Q2 2025 results and final Form 10-Q: total revenue USD 103.1m; Ohtuvayre net sales USD 102.9m; first quarterly net income of USD 11.9m; operating income USD 13.3m; cash USD 438.0m; accumulated deficit USD 567.1m; *"We are not currently subject to any material legal proceedings"*Proved the business model on a standalone basis just as it ceased to be standalone
18 August 2025DEFM14A published; Court Meeting and General Meeting convened for 24 September 2025Verona confirmed it was not subject to the UK Takeover Code, so no Rule 8 dealing disclosures were required
10 September 2025Employee communication (DEFA14A) from SVP Human Resources following a Verona–Merck employee town hall, covering retention agreements, integration timeline and severanceIntegration and retention risk actively managed; tone characterised as Merck valuing Verona's culture and expertise
16 September 2025Announcement of additional ENHANCE analyses for ERS International Congress 2025Continued medical-affairs investment through the pendency
24 September 2025Shareholders approve the Scheme of Arrangement and related resolutions, including a non-binding advisory vote on transaction-related compensationPenultimate condition satisfied; closing signalled for 7 October
6 October 2025High Court of Justice of England and Wales sanctions the SchemeFinal condition satisfied
7 October 2025Transaction completes. ADSs cease trading at a final reference price of USD 106.91. All continuing directors (Cunningham, Deschamps, Ebsworth, Edwards, Shah, Sinha, Zaccardelli and others) resign; Benjamin Lucas appointed Principal Executive Officer and director; Ebru Can Temucin appointed Principal Financial Officer, Principal Accounting Officer and directorEnd of independent existence
30 October 2025Verona Pharma Ireland Limited withdraws the EU MAA, stating that continuing the process was not aligned with current business objectives and portfolio strategy, while reserving the right to resubmitThe most consequential post-deal development. Europe removed from the near-term commercial map
10–13 November 2025CHMP meeting highlights formally record the Ohtuvayre withdrawalPublic confirmation via the EMA
3 February 2026Merck Q4 and FY2025 results: Ohtuvayre contributes USD 178m in Q4 2025, its first full quarter under Merck. Merck flags expected seasonality in early 2026 from Medicare deductible resets and notes growth in prescribing physicians and in prescriptions per physicianValidated the acquisition case in the first reporting period
30 April 2026Merck Q1 2026 results: Ohtuvayre USD 131m, down 26% sequentially, adversely affected by a CMS reimbursement change and Medicare deductible resets; prescription trends began recovering in MarchThe first genuine setback in the franchise's history — a reimbursement-driven, not demand-driven, contraction
April 2026MHRA has still not approved Ohtuvayre; no NICE appraisal initiatedUK commercialisation remains unresolved nearly a year after the June 2025 submission
4 August 2026Merck Q2 2026 results: Ohtuvayre USD 204m, up 56% sequentially, reflecting continued prescription demand — though Merck cautioned that results benefited from specialty pharmacy purchase timing expected to unwind in Q3 2026Recovery confirmed, but with an explicit warning that the quarter was flattered by channel stocking

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Income Statement: Revenue & Gross Profit: Total revenue, net rose from USD 0 Mn in FY2020 to USD 42.3 Mn in FY2024.
Verona Pharma PLC — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2020FY2021FY2022FY2023FY2024
Total revenue, net0400.5042.3
Total operating expenses excluding cost of sales74.3113.375.967.6194.3
Cost of sales000.302.6
Gross profit0400.1039.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.